Pappas Capital LLC
06/20/2011 | Press release | Archived content
Ultragenyx Announces Series A Financing
News | 06. 20. 2011
Ultragenyx Pharmaceutical
$45 million to support development of rare disease therapeutics
NOVATO, Calif., June 20, 2011--(EON: Enhanced Online News)--Ultragenyx Pharmaceutical Inc. today announced the closing of a $45 million Series A financing to support the development of rare disease therapeutics. The co-lead investors are TPG Biotech and Fidelity Biosciences, joined by European investor HealthCap, and Pappas Ventures. This funding will advance multiple rare disease product programs in the pipeline, as well as the development of new product candidates and partnerships. The lead product, UX-001, a first-in-class therapy for treatment of Hereditary Inclusion Body Myopathy (HIBM), is expected to enter the clinic in 2011.
Pappas Capital LLC published this content on June 20, 2011, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on April 22, 2026 at 10:06 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]